Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Switch to E/C/FTC/TAF daily · 1 trial · 4 indications
Change in mitochondrial function \[abnormal mitochondrial dynamics \[(cellular oxygen consumption (COC)\] over 12 months after switch of antiretrovirals.
| Arm | Type | Description |
|---|---|---|
| Switch to E/C/FTC/TAF daily | EXPERIMENTAL | Intervention: Participants will be asked to switch antiretrovirals (ART) for a period up to 12 months and mitochondrial physiology will be assessed using a variety of assays. The new ART will be 1. If the participant is on an ART other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to E/C/FTC/ tenofovir alafenamide (TAF) 1 tablet once daily for a period of 12 months. 2. If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months. |
| Name | Type | Description |
|---|---|---|
| Switch to E/C/FTC/TAF daily | DRUG | If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)\] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months. b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months. |
Inclusion Criteria: * Inclusion criteria for HIV negative participants All HIV negative participants must meet the following criteria: 1. 18 years of age or older 2. Understands and agrees to local STI reporting requirements 3. HIV negative at screening by self-report, with no significant medical...
Switch to E/C/FTC/TAF daily refers to switching HIV-positive patients to a once-daily fixed-dose combination of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide. It is an investigational strategy studied by Gilead Sciences in HIV/AIDS, evaluating whether switching to this TAF-based regimen reduces mitochondrial toxicity compared with tenofovir disoproxil fumarate.
Gilead Sciences, Inc. (ticker GILD) is the developer of the E/C/FTC/TAF fixed-dose combination and the switching strategy studied in HIV/AIDS. The company sponsored the Phase 1 trial NCT03251144, which compared the relative mitochondrial toxicity of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF).
The Switch to E/C/FTC/TAF daily regimen has been studied in a Phase 1 clinical trial. It is an investigational strategy and is not described as FDA approved for this use. The single Phase 1 study, NCT03251144, has been completed, and no active trials of this switching approach are listed.
One clinical trial studied this switching strategy: NCT03251144, titled Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF). The completed Phase 1 trial enrolled 26 healthy adult volunteers in the United States, was uncontrolled, and was not randomized or double blinded.
It is studied as a once-daily switch option for people living with HIV/AIDS, replacing a tenofovir disoproxil fumarate (TDF) containing regimen with a tenofovir alafenamide (TAF) based combination. The Phase 1 trial NCT03251144 assessed relative mitochondrial toxicity between TAF and TDF in 26 healthy volunteers, a marker of antiviral drug adverse effects.